Table 1 Frequent (≥5%) Treatment-emergent Adverse Events with Exenatide Once Weekly During Weeks 0 to 30 and Weeks 30 to 104
Adverse Event | Weeks 0 to 30 (n = 148*) (% of patients) | Weeks 30 to 104 (n = 258†) (% of patients) |
|---|---|---|
Nausea | 27 | 12 |
Vomiting | 11 | 9 |
Diarrhea | 15 | 12 |
Constipation | 11 | 5 |
Dyspepsia | 7 | 3 |
Gastroesophageal reflux disease | 7 | 4 |
Injection site pruritus | 18 | 4 |
Injection site erythema | 7 | 4 |
Urinary tract infection | 10 | 9 |
Gastroenteritis viral | 9 | 7 |
Nasopharyngitis | 7 | 16 |
Upper respiratory tract infection | 8 | 24 |
Sinusitis | 5 | 12 |
Influenza | 1 | 5 |
Headache | 6 | 5 |
Fatigue | 6 | 4 |
Back pain | 5 | 7 |
Arthralgia | 5 | 6 |
Pain in extremity | 1 | 6 |